Clinical trials Below are current clinical trials.45 studies in Nephrology and Hypertension (open studies only). Filter this list of studies by location, status and more. Biobank Protocol, Rare Diseases Clinical Research Network Rochester, Minn. This study is being done to obtain samples from patients with primary hyperoxaluria, cystinuria, adenine phosphoribosyl transferase (APRT) deficiency, and Dent disease, and from their family members, for use in future research. A Study to Form a Database of Children with Kidney Stone Disease Rochester, Minn. The purpose of this study is to establish a database to collect and analyze information on metabolic and environmental risk factors for kidney stone formation in children. Obstructive Sleep Apnea Among Somali-Americans Rochester, Minn. The purpose of this study is to advance the understanding of obstructive sleep apnea as it relates to different ethnic origins as well as sex differences. The investigators will compare Somali patients with known obstructive sleep apnea (OSA) to individuals without OSA, and to individuals of other ethnic/racial origins to determine the risk factors (genetic and/or physiologic) associated with developing cardiovascular diseases. This will help the investigators to understand the unique sleep pathology of individuals of African descent. A Study to Evaluate How Semaglutide Works Compared to Placebo in People with Type 2 Diabetes and Chronic Kidney Disease Rochester, Minn. The purpose of this study is to evaluate whether or not semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes. Participants will receive semaglutide (active medicine) or placebo ('dummy medicine'). This is known as participants' study medicine - which treatment participants get is decided by chance. Semaglutide is a medicine, doctors can prescribe in some countries for the treatment of type 2 diabetes. Participants will get the study medicine in a pen. Participants will use the pen to inject the medicine in a skin fold once a week. The study will close when there is enough information collected to show clear result of the study. The total time participants will be in this study is about 3 to 5 years, but it could be longer. A Study to Evaluate Noninvasive Ultrasound Elastography of Kidney and Lung in Assessment of Volume Status in ICU Patients Rochester, Minn. The primary purpose of this study is to assess the feasibility of performing lung and kidney and lung ultrasound elastography among patients with critical illness from different etiologies that could be associated with volume overload. A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease Rochester, Minn., Jacksonville, Fla. The purpose of ths study is to assess the safety and tolerability of RGLS8429. Addiitionally, to assess the impact of RGLS8429 on ADPKD biomarkers Other objectives are o assess the impact of RGLS8429 on height-adjusted total kidney volume (htTKV) and to characterize the pharmacokinetic (PK) properties of RGLS8429 -To assess the impact of RGLS8429 on renal function. A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea Rochester, Minn. Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue. Monogenic Kidney Stone - Genetic Testing Rochester, Minn. 90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff. Evaluation of the Total Kidney Volume AI Algorithm Rochester, Minn. The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly variable and typically characterized by progressive enlargement of cysts within the kidneys. ADPKD is a leading cause of end-stage renal disease. Recently, a new medication called Tolvaptan has been approved by the FDA to slow progression of ADPKD. Accurate, MR based kidney volume measurements are the best parameter for following the progression of ADPKD, and are suggested be acquired to measure progression and effects of Tolvaptan. However, making these slice-by-slice volume measurements can be extremely time consuming when done manually. The purpose of this work is to evaluate an AI algorithm to make the measurements. The results of the algorithm will be reviewed by a qualified radiologist familiar with the algorithm’s results. If the radiologist agrees with the results, kidney volumes (left, right and combined) will be recorded for clinical use. The usage of the algorithm in this setting (with review by radiologist, and manual correction) is a minimal risk to the patients: a failure of the algorithm will have no impact on treatment and errors will be caught and corrected by the QC process. Because the algorithm will not be used solely for diagnosis or inform treatment without the confirmation of the diagnosis by another, medically established diagnostic product or procedure this study constitutes minimal risk to patients. Study to Evaluate Clinical Complications, Pattern of Kidney Function Decline and Identification of Clinical Variables Related to Progression of Autosomal Dominant Polycystic Kidney Disease Rochester, Minn. The purpose of this study is to evaluate clinical complications, pattern of kidney function decline and identification of clinical variables related to progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Pagination Clinical studies PrevPrevious Page Go to page 22 Go to page 33 Go to page 44 Go to page 55 NextNext Page Request an appointment Expertise & rankingsResearch June 19, 2024 Share on: FacebookTwitter Nephrology and HypertensionSectionsRequest an appointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchCosts & insuranceNews from Mayo ClinicReferrals Research: It's all about patients Show transcript for video Research: It's all about patients [MUSIC PLAYING] Joseph Sirven, M.D., Professor of Neurology, Mayo Clinic: Mayo's mission is about the patient. The patient comes first. So the mission and research here is to advance how we can best help the patient, how to make sure the patient comes first in care. So in many ways, it's a cycle. It can start with as simple as an idea worked on in a laboratory, brought to the patient bedside, and if everything goes right — and let's say it's helpful or beneficial — then brought on as a standard approach. And I think that is one of the unique characteristics of Mayo's approach to research — that patient-centeredness — that really helps to put it in its own spotlight. SectionsRequest an appointmentOverviewTests & proceduresConditions treatedDoctorsSpecialty groupsExpertise & rankingsClinical trialsResearchCosts & insuranceNews from Mayo ClinicReferrals ORG-20464466 Medical Departments & Centers Nephrology and Hypertension